RT期刊文章SR电子T1预防偏头痛的褪黑激素摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP 1527 OP 1532首页 10.1212 / WNL。0 b013e3181f9618c VO 75是17 A1卡尔·b·Alstadhaug A1弗朗西斯Odeh A1 Rolf Salvesen A1 Svein i Bekkelund年2010 UL //www.ez-admanager.com/c首页ontent/75/17/1527.abstract AB背景:前一个开放研究褪黑激素的生理系统的关键物质,对偏头痛的影响表明,安慰剂对照研究。方法:随机、双盲、安慰剂对照2进行交叉研究中心。男性和女性,年龄在18 - 65岁,偏头痛,但健康,体验每个月2 - 7日袭击,是从普通人群招募的。四周后试车阶段,48个受试者被随机分配接受安慰剂或延长释放褪黑激素(Circadin®, Neurim制药有限公司,特拉维夫,以色列)2毫克的剂量在睡前1小时8周。冲刷为期6周治疗后切换。主要结果是偏头痛发作频率(AF)。次要终点是睡眠质量评估匹兹堡睡眠质量指数(PSQI)。结果:46个受试者完成了研究(96%)。在试车阶段,平均房颤期间每月4.2(±1.2)和褪黑激素治疗房颤为2.8 (±1.6)。 However, the reduction in AF during placebo was almost equal (p = 0.497). Absolute risk reduction was 3% (95% confidence interval −15 to 21, number needed to treat = 33). A highly significant time effect was found. The mean global PSQI score did not improve during treatment (p = 0.09). Conclusion: This study provides Class I evidence that prolonged-release melatonin (2 mg 1 hour before bedtime) does not provide any significant effect over placebo as migraine prophylaxis. Classification of evidence: This study provides Class I evidence that 2 mg of prolonged release melatonin given 1 hour before bedtime for a duration of 8 weeks did not result in a reduction in migraine frequency compared with placebo (p = 0.497).